Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Norepinephrine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    133 result(s) found for: Norepinephrine. Displaying page 5 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2009-010798-19 Sponsor Protocol Number: FE202158CS02 Start Date*: 2009-10-12
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A randomized, double-blind, placebo-controlled, infusion proof-of-concept trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ascending doses of FE 202158 in pat...
    Medical condition: Vasodilatory hypotension in early septic shock
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-002268-15 Sponsor Protocol Number: EMPA-1 Start Date*: 2016-09-29
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: A PHASE II, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE CENTER STUDY OF THE EFFECT OF EMPAGLIFLOZIN, A SGLT-2 INHIBITOR, ON ENDOGENOUS GLUCOSE PRODUCTION AND PLASMA GLUCAGON LE...
    Medical condition: Patients with end-stage renal disease (ESRD) with or without Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    21.1 100000004857 10014647 End stage renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004881-20 Sponsor Protocol Number: NORDIST Start Date*: 2021-10-18
    Sponsor Name:AZIENDA USL TOSCANA SUD EST Sezione di Arezzo
    Full Title: Comparison of norepinephrine and dobutamine in patients in cardiogenic shock
    Medical condition: Patients over 18 years of age with cardiogenic shock
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10040563 Shock cardiogenic LLT
    20.0 10007541 - Cardiac disorders 10040563 Shock cardiogenic LLT
    20.0 10007541 - Cardiac disorders 10007625 Cardiogenic shock PT
    20.0 10007541 - Cardiac disorders 10007625 Cardiogenic shock PT
    20.0 10007541 - Cardiac disorders 10007625 Cardiogenic shock PT
    20.0 10007541 - Cardiac disorders 10007625 Cardiogenic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005687-27 Sponsor Protocol Number: TAK-242_301 Start Date*: 2008-08-06
    Sponsor Name:Takeda Global Research & Development Centre (Europe), Ltd. [...]
    1. Takeda Global Research & Development Centre (Europe), Ltd.
    2. Takeda Global Research & Development Centre (Europe), Ltd.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of TAK-242 Versus Placebo in Subjects With Sepsis Induced Cardiovascular and Respiratory Failure
    Medical condition: Septic shock and respiratory failure.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040070 Septic shock PT
    9.1 10038695 Respiratory failure PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) FI (Completed) CZ (Prematurely Ended) HU (Prematurely Ended) FR (Completed) AT (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-002560-34 Sponsor Protocol Number: F1J-US-HMFR(b) Start Date*: 2008-09-02
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Duloxetine HCl in Patients with Central Neuropathic Pain Due to Multiple Sclerosis
    Medical condition: Central neuropathic pain due to Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000204-15 Sponsor Protocol Number: 060286 Start Date*: 2017-08-08
    Sponsor Name:Professor, DMSc Tina Vilsbøll
    Full Title: Glimepiride monotherapy vs. combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes
    Medical condition: "Hepatocyte nuclear factor 1-alfa diabetes", also called "Maturity onset diabetes of the young type 3"'. It is a monogenic form of inherited diabetes.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10026948 Maturity-onset diabetes of the young LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002358-22 Sponsor Protocol Number: C1201 Start Date*: 2012-08-06
    Sponsor Name:Biologische Heilmittel Heel GmbH
    Full Title: NEUPRO DB, efficacy profile of Neurexan in an experimental acute stress setting – an explorative double blind study in healthy probands
    Medical condition: Neurexan to be effective in fostering mental balance by reducing tension and nervousness during acute stress setting in healthy probands
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004848 10042219 Stress test LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002359-40 Sponsor Protocol Number: C1202 Start Date*: 2012-07-18
    Sponsor Name:Biologische Heilmittel Heel GmbH
    Full Title: NEUPRO OL, Efficacy profile of Neurexan® in an experimental acute stress setting – an explorative open-label study in healthy probands
    Medical condition: Neurexan to be effective in fostering mental balance by reducing tension and nervousness during acute stress setting in healthy probands
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004848 10042219 Stress test LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001436-33 Sponsor Protocol Number: NP25620 Start Date*: 2011-11-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-blind, parallel-group study of the safety and efficacy of RO4917523 versus placebo, as adjunctive therapy in patients with major depressive disorder with inadequate response to...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10025463 Major depressive disorder, single episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002108-24 Sponsor Protocol Number: SLC022/201 Start Date*: 2009-03-10
    Sponsor Name:Solace Pharmaceuticals Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral SLC022 300 mg TID, a Glial Cell Modulating Agent, Versus Placebo in the Treatme...
    Medical condition: Post herpetic neuralgia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036376 Post herpetic neuralgia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003714-68 Sponsor Protocol Number: 1744/2017 Start Date*: 2017-11-15
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of Supplemental Oxygen on Perioperative Brain Natriuretic Peptide Concentration in Cardiac Risk Patients - A prospective randomized clinical trial
    Medical condition: Evaluation of the effect of 80% versus 30% supplemental oxygen administration during major abdominal surgery on postoperative brain natriuretic peptide concentration.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10059883 Fraction of inspired oxygen PT
    20.0 100000173317 10050322 Oxygen supplementation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003973-41 Sponsor Protocol Number: 000133 Start Date*: 2015-06-22
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A Double-blind, Randomised, Placebo-controlled, Phase 2b/3 Adaptive Clinical Trial Investigating the Efficacy and Safety of Selepressin as Treatment for Patients with Vasopressor-dependent Septic S...
    Medical condition: Vasopressor-dependent Septic Shock
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) FR (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005241-16 Sponsor Protocol Number: CKN-DASI120-RYGB Start Date*: 2021-03-19
    Sponsor Name:Center for Clinical Metabolic Research at Herlev-Gentofte Hospital
    Full Title: Ready-to-use dasiglucagon for the treatment of postprandial hypoglycaemia in Roux-en-Y gastric bypass operated patients
    Medical condition: Postprandial hyperinsulinemic hypoglycaemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10079748 Reactive hypoglycaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-002151-10 Sponsor Protocol Number: NEUROPROTECTpost-CA Start Date*: 2015-08-07
    Sponsor Name:UZ Leuven
    Full Title: Neuroprotective goal directed hemodynamic optimization in post-cardiac arrest patients: a randomized controlled trial (the NEUROPROTECT post-CA trial)
    Medical condition: post-cardiac arrest patients
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10047283 Ventricular arrhythmias and cardiac arrest HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001563-74 Sponsor Protocol Number: PHRCN2018/LEVOHEARTSHOCK-LEVY/YB Start Date*: 2020-07-24
    Sponsor Name:CHRU de Nancy
    Full Title: Effect of early use of levosimendan versus placebo on top of a conventional strategy of inotrope use on a combined morbidity-mortality endpoint in patients with cardiogenic shock. LevoHeartShock St...
    Medical condition: Cardiogenic shock
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007625 Cardiogenic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002126-90 Sponsor Protocol Number: 2019/399/HP Start Date*: 2021-03-09
    Sponsor Name:Direction de la Recherche Clinique et de l’Innovation – CHU de Rouen
    Full Title: Opioid-Free Anesthesia in Cardiac Surgery
    Medical condition: Patients undergoing cardiac surgery under extracorporeal circulation with at least one aorto-coronary bypass and the removal of at least one internal mammary artery
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10066124 Extracorporeal circulation PT
    20.0 100000004863 10017501 Functional disturbances following cardiac surgery LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005860-69 Sponsor Protocol Number: ODEN Start Date*: 2021-05-10
    Sponsor Name:University of Gothenburg
    Full Title: OSU6162 as add-on in SSRI/SNRI-resistant depression (ODEN): a double-blind, placebo-controlled evaluation of efficacy and safety.
    Medical condition: Depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001994-27 Sponsor Protocol Number: 2006B180 Start Date*: 2007-09-03
    Sponsor Name:Academisch Medisch Centrum
    Full Title: The effect of beta-adrenergic receptor blockade on sympathetic activity and coagulation in patients with heart failure (BACH-F study)
    Medical condition: Congestive heart failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000302-29 Sponsor Protocol Number: AlbuCAT Start Date*: 2019-07-31
    Sponsor Name:Fundació Clinic per a la Recerca Biomèdica
    Full Title: ALBUMIN FOR MANAGEMENT OF HYPERVOLEMIC HYPONATREMIA IN PATIENTS WITH DECOMPENSATED CIRRHOSIS. A PROOF OF CONCEPT STUDY
    Medical condition: HYPERVOLEMIC HYPONATREMIA IN PATIENTS WITH DECOMPENSATED CIRRHOSIS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10009211 Cirrhosis liver LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005441-38 Sponsor Protocol Number: F1K-MC-EVDP Start Date*: 2008-03-07
    Sponsor Name:Eli Lilly and Company
    Full Title: Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock
    Medical condition: Septic shock
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) NL (Completed) FR (Completed) BE (Completed) IT (Completed) PT (Completed) FI (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 00:01:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA